Methods of treating vascular diseases characterized by nitric oxide insufficiency related applications
AssigneeNitroMed, Inc.
InventorsJoseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
Life of this patent
Estimating the term…
Loading patent…
AssigneeNitroMed, Inc.
InventorsJoseph Loscalzo, Joseph A. Vita, Michael D. Loberg, Manuel Worcel
Estimating the term…
The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).
A sustained release formulation comprising a therapeutically effective amount of at least one antioxidant and at least one of isosorbide dinitrate and isosorbide mononitrate.
An orally administerable composition comprising about 37.5 mg hydralazine hydrochloride and about 10 mg isosorbide dinitrate or about 37.5 mg hydralaiine hydrochloride and about 20 mg isosorbide dinitrate.
An orally administerable composition comprising about 75 mg hydralazine hydrochloride and about 20 mg isosorbide dinitrate or about 75 mg hydralazine hydrochloride and about 40 mg isosorbide dinitrate.
A method of treating and/or preventing a vascular disease characterized by nitric oxide insufficiency in a patient comprising administering to the patient a therapeutically effective amount of at least one antioxidant, or a pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase or a pharmaceutically acceptable salt thereof.
A method of treating Raynaud's syndrome in a patient comprising administering to the patient a therapeutically effective amount of at least one antioxidant, or a pharmaceutically acceptable salt thereof, and at least one compound that donates, transfers, or releases nitric oxide, or induces the production of endogenous nitric oxide or endothelium-derived relaxing factor or is a substrate for nitric oxide synthase or a pharmaceutically acceptable salt thereof.
A method of treating and/or preventing a vascular disease characterized by nitric oxide insufficiency in a patient comprising administering to the patient a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, or a mixture thereof.
A transdermal patch comprising a therapeutically effective amount of at least one antioxidant and at least one of isosorbide dinitrate and isosorbide mononitrate.
Dependencies are inferred from the claim text.